
On Thursday morning, Lundbeck reported receiving positive data for the company's antidepressant Brintellix (generic name vortioxetin). In the firm's Relieve study, the drug has shown promise in improving severely depressed patients' ability to function.
A total of 994 patients took part in this study, which Lundbeck states shows significant improvements in overall functioning after three months and further improvements following a six-month period.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app